— Know what they know.
Not Investment Advice
Also trades as: GMAB.CO (CPH) · $vol 55M · GNMSF (OTC) · $vol 1M · GE9.F (FSX) · $vol 0M

GMAB NASDAQ

Genmab A/S
1W: +16.1% 1M: +26.5% 3M: +54.1% YTD: +40.5% 1Y: +49.6% 3Y: +56.0% 5Y: +0.4%
$44.67
-0.01 (-0.03%)
 
Weekly Expected Move ±8.1%
$37 $40 $44 $47 $51
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Buy · Power 70 · $27.5B mcap · 587M float · 0.486% daily turnover · Short 61% of daily vol
Credit Risk of going bust: lower than 69% of companies Debt: 16.1% of company value Bonds: $301.5M held by 241 funds, 181 bp over Treasuries → details ▾
If the stock fell to about $0.65 (down 99%), Genmab A/S would be worth roughly what it owes.
Total debt $5.27B against a stock market value of $27.48B.
Distance to default 7.47 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.71B (short-term plus half of long-term), stock volatility 35.1%; Altman Z'' 3.61. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Oct Typical
☀️
Sunny
+24.3% YTD avg
Midterm Year
⛈️
Stormy
-10.4% YTD avg
2026 Now
☀️
Sunny
Above typical
20yr Avg YTD
+24.3%
Day 206 of 252
Midterm Year YTD
-10.4%
Presidential cycle avg
2026 YTD
+40.4%
Above 20yr avg
Typical Vol
35%
Annualized
Monthly Weather Forecast
Jan
20yr
🌫️
-1.6%
Midterm
☁️
-0.2%
35% win 38% vol
Feb
20yr
💨
+4.5%
Midterm
☀️
+5.2%
47% win 42% vol
Mar
20yr
🌫️
+3.6%
Midterm
☁️
+0.2%
47% win 56% vol
Apr
20yr
⛅
+4.9%
Midterm
🌧️
-3.5%
47% win 30% vol
May
20yr
💨
+10.5%
Midterm
⛈️
-21.4%
53% win 45% vol
Jun
20yr
💨
+8.4%
Midterm
⛈️
-19.1%
56% win 37% vol
Jul
20yr
💨
+13.2%
Midterm
⛈️
-11.2%
78% win 77% vol
Aug
20yr
⛈️
+18.7%
Midterm
⛈️
-10.5%
56% win 54% vol
Sep
20yr
⛅
+23.2%
Midterm
⛈️
-13.1%
39% win 31% vol
Oct
20yr
💨
+23.3%
Midterm
⛈️
-10.2%
50% win 35% vol
Now: +25.2%
Nov
20yr
💨
+29.6%
Midterm
⛅
+3.1%
53% win 56% vol
Dec
20yr
💨
+1.6%
Midterm
☀️
+4.0%
47% win 38% vol
Seasonality (20yr)
Updated: 2026-10-27
YTD: +40.4%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms